Concepts (104)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoma | 11 | 2023 | 140 | 5.500 |
Why?
|
| Bone Neoplasms | 10 | 2023 | 118 | 4.430 |
Why?
|
| Soft Tissue Neoplasms | 5 | 2022 | 52 | 1.910 |
Why?
|
| Retrospective Studies | 16 | 2023 | 2994 | 1.360 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2023 | 202 | 1.080 |
Why?
|
| Giant Cell Tumor of Bone | 3 | 2022 | 16 | 0.910 |
Why?
|
| Margins of Excision | 2 | 2022 | 29 | 0.850 |
Why?
|
| Lymphatic Metastasis | 2 | 2021 | 86 | 0.830 |
Why?
|
| Chondrosarcoma | 1 | 2023 | 38 | 0.800 |
Why?
|
| Spinal Neoplasms | 1 | 2023 | 34 | 0.800 |
Why?
|
| Embolization, Therapeutic | 1 | 2023 | 53 | 0.780 |
Why?
|
| Kidney Neoplasms | 1 | 2023 | 75 | 0.770 |
Why?
|
| Neutrophils | 1 | 2023 | 91 | 0.770 |
Why?
|
| Humans | 23 | 2023 | 22958 | 0.750 |
Why?
|
| Sarcoma, Synovial | 1 | 2022 | 11 | 0.730 |
Why?
|
| Prognosis | 7 | 2023 | 730 | 0.700 |
Why?
|
| Lymphatic Vessels | 1 | 2021 | 8 | 0.680 |
Why?
|
| Myxosarcoma | 1 | 2020 | 3 | 0.670 |
Why?
|
| Osteosarcoma | 1 | 2021 | 36 | 0.670 |
Why?
|
| Fibrosarcoma | 1 | 2020 | 9 | 0.670 |
Why?
|
| Prosthesis-Related Infections | 1 | 2022 | 177 | 0.630 |
Why?
|
| Osteoarthritis | 1 | 2022 | 283 | 0.570 |
Why?
|
| Arthroplasty, Replacement, Hip | 2 | 2022 | 686 | 0.570 |
Why?
|
| Treatment Outcome | 6 | 2023 | 2941 | 0.480 |
Why?
|
| Arthroplasty, Replacement, Knee | 2 | 2022 | 560 | 0.480 |
Why?
|
| Child | 4 | 2021 | 1157 | 0.420 |
Why?
|
| Young Adult | 5 | 2021 | 1651 | 0.400 |
Why?
|
| Survival Rate | 4 | 2021 | 318 | 0.390 |
Why?
|
| Limb Salvage | 2 | 2023 | 12 | 0.390 |
Why?
|
| Adolescent | 4 | 2021 | 1881 | 0.380 |
Why?
|
| Neoadjuvant Therapy | 3 | 2022 | 62 | 0.370 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2022 | 31 | 0.360 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2022 | 35 | 0.360 |
Why?
|
| Adult | 7 | 2022 | 6927 | 0.350 |
Why?
|
| Follow-Up Studies | 4 | 2022 | 1412 | 0.340 |
Why?
|
| Neoplasm Staging | 2 | 2022 | 356 | 0.330 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 274 | 0.320 |
Why?
|
| Middle Aged | 6 | 2021 | 7911 | 0.270 |
Why?
|
| Prospective Studies | 2 | 2023 | 1493 | 0.270 |
Why?
|
| Male | 7 | 2021 | 12466 | 0.220 |
Why?
|
| Female | 6 | 2021 | 12958 | 0.220 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 3728 | 0.220 |
Why?
|
| Biopsy | 2 | 2023 | 189 | 0.210 |
Why?
|
| Curettage | 2 | 2022 | 9 | 0.210 |
Why?
|
| Lower Extremity | 1 | 2023 | 33 | 0.210 |
Why?
|
| Surgical Flaps | 1 | 2023 | 50 | 0.200 |
Why?
|
| Bone Cements | 2 | 2022 | 78 | 0.200 |
Why?
|
| Blood Loss, Surgical | 1 | 2023 | 53 | 0.200 |
Why?
|
| Lymphocyte Count | 1 | 2023 | 16 | 0.200 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 17 | 0.200 |
Why?
|
| Reoperation | 3 | 2022 | 743 | 0.200 |
Why?
|
| Lymphocytes | 1 | 2023 | 51 | 0.200 |
Why?
|
| Preoperative Care | 1 | 2023 | 107 | 0.200 |
Why?
|
| Femur | 2 | 2022 | 298 | 0.200 |
Why?
|
| Necrosis | 1 | 2022 | 24 | 0.190 |
Why?
|
| Plasma Gases | 1 | 2022 | 2 | 0.190 |
Why?
|
| Infant | 2 | 2021 | 483 | 0.190 |
Why?
|
| Replantation | 1 | 2022 | 9 | 0.190 |
Why?
|
| Child, Preschool | 2 | 2021 | 567 | 0.190 |
Why?
|
| Infant, Newborn | 2 | 2021 | 537 | 0.190 |
Why?
|
| Lung Neoplasms | 2 | 2021 | 539 | 0.190 |
Why?
|
| Aged | 4 | 2021 | 7448 | 0.180 |
Why?
|
| Printing, Three-Dimensional | 1 | 2021 | 6 | 0.180 |
Why?
|
| Metastasectomy | 1 | 2021 | 7 | 0.180 |
Why?
|
| Time-to-Treatment | 1 | 2022 | 27 | 0.180 |
Why?
|
| Radiopharmaceuticals | 1 | 2022 | 48 | 0.180 |
Why?
|
| Positron-Emission Tomography | 1 | 2022 | 72 | 0.180 |
Why?
|
| Allografts | 1 | 2021 | 147 | 0.170 |
Why?
|
| SEER Program | 1 | 2021 | 34 | 0.170 |
Why?
|
| Neoplasm Grading | 1 | 2021 | 50 | 0.170 |
Why?
|
| Leiomyosarcoma | 1 | 2021 | 23 | 0.170 |
Why?
|
| Neoplasm Invasiveness | 1 | 2021 | 88 | 0.170 |
Why?
|
| Hemipelvectomy | 1 | 2020 | 2 | 0.170 |
Why?
|
| Pelvic Neoplasms | 1 | 2020 | 8 | 0.170 |
Why?
|
| Disease-Free Survival | 1 | 2021 | 171 | 0.170 |
Why?
|
| Ganglion Cysts | 1 | 2020 | 6 | 0.160 |
Why?
|
| Contracture | 1 | 2020 | 11 | 0.160 |
Why?
|
| Anti-Bacterial Agents | 1 | 2022 | 362 | 0.150 |
Why?
|
| Elbow Joint | 1 | 2020 | 113 | 0.150 |
Why?
|
| Tibia | 2 | 2010 | 197 | 0.150 |
Why?
|
| Time Factors | 1 | 2022 | 1262 | 0.140 |
Why?
|
| Hip Prosthesis | 1 | 2022 | 437 | 0.130 |
Why?
|
| Spinal Fusion | 1 | 2020 | 429 | 0.100 |
Why?
|
| Patellar Ligament | 1 | 2010 | 35 | 0.080 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2010 | 30 | 0.080 |
Why?
|
| Cell Division | 1 | 2022 | 80 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 35 | 0.040 |
Why?
|
| Apoptosis | 1 | 2022 | 196 | 0.040 |
Why?
|
| Pneumonectomy | 1 | 2021 | 76 | 0.040 |
Why?
|
| Lung | 1 | 2021 | 138 | 0.040 |
Why?
|
| Joint Capsule Release | 1 | 2020 | 6 | 0.040 |
Why?
|
| Elbow | 1 | 2020 | 40 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 295 | 0.040 |
Why?
|
| Prosthesis Design | 1 | 2022 | 384 | 0.040 |
Why?
|
| Mutation | 1 | 2021 | 330 | 0.040 |
Why?
|
| Prosthesis Failure | 1 | 2022 | 414 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2021 | 1417 | 0.030 |
Why?
|
| Risk Factors | 1 | 2022 | 1971 | 0.030 |
Why?
|
| Thoracoscopy | 1 | 2010 | 22 | 0.020 |
Why?
|
| Ilium | 1 | 2010 | 28 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2010 | 82 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2010 | 336 | 0.020 |
Why?
|
| Arthralgia | 1 | 2010 | 100 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2010 | 577 | 0.020 |
Why?
|